Dormancy of metastatic melanoma

Pigment Cell and Melanoma Research

Volumn 23, Issue 1, 2010, Pages 41-56

  Ossowski, Liliana ^a   Aguirre Ghiso, Julio A ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

B Raf N Ras; GNAQ; Micrometastasis; Residual disease

Indexed keywords

B RAF KINASE; FIBRILLAR COLLAGEN; GUANINE NUCLEOTIDE BINDING PROTEIN ALPHA SUBUNIT; TRANSFORMING GROWTH FACTOR BETA;

ADJUVANT THERAPY; ANGIOGENESIS; CANCER PATIENT; CANCER RECURRENCE; CANCER THERAPY; COMPARATIVE STUDY; DISEASE FREE SURVIVAL; DISSEMINATED CANCER; DORMANCY; HUMAN; MELANOMA; MELANOMA CELL; METASTASIS; MICROENVIRONMENT; ONCOGENE N RAS; REVIEW; SIGNAL TRANSDUCTION; SKIN METASTASIS; TUMOR CELL; TUMOR GROWTH; TUMOR IMMUNOLOGY; UVEA MELANOMA;

ANIMALS; CELL TRANSFORMATION, NEOPLASTIC; DISEASE PROGRESSION; EARLY DETECTION OF CANCER; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MELANOMA; MUTATION; NEOPLASM METASTASIS; NEOPLASM RECURRENCE, LOCAL; SKIN NEOPLASMS; UVEAL NEOPLASMS;

EID: 74349102988     PISSN: 17551471     EISSN: 1755148X     Source Type: Journal    
DOI: 10.1111/j.1755-148X.2009.00647.x     Document Type: Review

References (162)

1. Aasen, T., Raya, A., Barrero, M.J. et al. (2008). Efficient and rapid generation of induced pluripotent stem cells from human keratinocytes. Nat. Biotechnol. 26, 1276 1284.
2. Aguirre Ghiso, J.A. (2002). Inhibition of FAK signaling activated by urokinase receptor induces dormancy in human carcinoma cells in vivo. Oncogene 21, 2513 2524.
3. Aguirre Ghiso, J.A., Kovalski, K. Ossowski, L. (1999). Tumor dormancy induced by downregulation of urokinase receptor in human carcinoma involves integrin and MAPK signaling. J. Cell Biol. 147, 89 104.
4. Aguirre-Ghiso, J.A. (2007). Models, mechanisms and clinical evidence for cancer dormancy. Nat. Rev. Cancer 7, 834 846.
5. Aguirre-Ghiso, J.A., Estrada, Y., Liu, D. Ossowski, L. (2003). ERK(MAPK) activity as a determinant of tumor growth and dormancy; regulation by p38(SAPK). Cancer Res. 63, 1684 1695.
6. Alison, M.R., Islam, S. Lim, S.M. (2009). Number crunching in the cancer stem cell market. Breast Cancer Res. 11, 302.
7. Arenberger, P., Arenbergerova, M., Vohradnikova, O. Kremen, J. (2008). Early detection of melanoma progression by quantitative real-time RT-PCR analysis for multiple melanoma markers. Keio J. Med. 57, 57 64.
8. Bakalian, S., Marshall, J.C., Faingold, D., Logan, P., Antecka, E. Burnier, M.N. Jr. (2007). Expression of nm23-H1 in uveal melanoma. Melanoma Res. 17, 284 290.
9. Balic, M., Lin, H., Young, L., Hawes, D., Giuliano, A., Mcnamara, G., Datar, R.H. Cote, R.J. (2006). Most early disseminated cancer cells detected in bone marrow of breast cancer patients have a putative breast cancer stem cell phenotype. Clin. Cancer Res. 12, 5615 5621.
10. Barnhill, R.L., Piepkorn, M.W., Cochran, A.J., Flynn, E., Karaoli, T. Folkman, J. (1998). Tumor vascularity, proliferation, and apoptosis in human melanoma micrometastases and macrometastases. Arch. Dermatol. 134, 991 994.
11. Bauer, J., Kilic, E., Vaarwater, J., Bastian, B.C., Garbe, C. De Klein, A. (2009). Oncogenic GNAQ mutations are not correlated with disease-free survival in uveal melanoma. Br. J. Cancer 101, 813 815.
12. Belmar-Lopez, C., Mancheno-Corvo, P., Saornil, M.A., Baril, P., Vassaux, G., Quintanilla, M. Martin-Duque, P. (2008). Uveal vs. cutaneous melanoma. Origins and causes of the differences. Clin. Transl. Oncol. 10, 137 142.
13. Bhat, K.M., Maddodi, N., Shashikant, C. Setaluri, V. (2006). Transcriptional regulation of human MAP2 gene in melanoma: role of neuronal bHLH factors and Notch1 signaling. Nucleic Acids Res. 34, 3819 3832.
14. Bidard, F.C., Vincent-Salomon, A., Sigal-Zafrani, B., Rodrigues, M., Dieras, V., Mignot, L., Sastre-Garau, X., Poupon, M.F. Pierga, J.Y. (2008). Time to metastatic relapse and breast cancer cells dissemination in bone marrow at metastatic relapse. Clin. Exp. Metastasis 25, 871 875.
15. Birck, A., Ahrenkiel, V., Zeuthen, J., Hou-Jensen, K. Guldberg, P. (2000). Mutation and allelic loss of the PTEN/MMAC1 gene in primary and metastatic melanoma biopsies. J. Invest. Dermatol. 114, 277 280.
16. Boisvert-Adamo, K. Aplin, A.E. (2006). B-RAF and PI-3 kinase signaling protect melanoma cells from anoikis. Oncogene 25, 4848 4856.
17. Braun, S., Vogl, F.D., Naume, B. et al. (2005). A pooled analysis of bone marrow micrometastasis in breast cancer. N. Engl. J. Med. 353, 793 802. (Pubitemid 41215488)
18. Callejo, S.A., Antecka, E., Blanco, P.L., Edelstein, C. Burnier, M.N. Jr. (2007). Identification of circulating malignant cells and its correlation with prognostic factors and treatment in uveal melanoma. A prospective longitudinal study. Eye 21, 752 759.
19. Cameron, M.D., Schmidt, E.E., Kerkvliet, N., Nadkarni, K.V., Morris, V.L., Groom, A.C., Chambers, A.F. Macdonald, I.C. (2000). Temporal progression of metastasis in lung: cell survival, dormancy, and location dependence of metastatic inefficiency. Cancer Res. 60, 2541 2546.
20. Chambers, A.F., Groom, A.C. Macdonald, I.C. (2002). Dissemination and growth of cancer cells in metastatic sites. Nat. Rev. Cancer 2, 563 572.
21. Conner, S.R., Scott, G. Aplin, A.E. (2003). Adhesion-dependent activation of the ERK1/2 cascade is by-passed in melanoma cells. J. Biol. Chem. 278, 34548 34554.
22. Crowley, N.J. Seigler, H.F. (1990a). Late recurrence of malignant melanoma. Analysis of 168 patients. Ann. Surg. 212, 173 177.
23. Crowley, N.J. Seigler, H.F. (1990b). The role of elective lymph node dissection in the management of patients with thick cutaneous melanoma. Cancer 66, 2522 2527.
24. Dahl, C. Guldberg, P. (2007). The genome and epigenome of malignant melanoma. APMIS 115, 1161 1176.
25. Dai, D.L., Martinka, M. Li, G. (2005). Prognostic significance of activated Akt expression in melanoma: a clinicopathologic study of 292 cases. J. Clin. Oncol. 23, 1473 1482.
26. Dankort, D., Curley, D.P., Cartlidge, R.A., Nelson, B., Karnezis, A.N., Damsky, W.E. Jr., You, M.J., Depinho, R.A., Mcmahon, M. Bosenberg, M. (2009). Braf(V600E) cooperates with Pten loss to induce metastatic melanoma. Nat. Genet. 41, 544 552.
27. Davies, H., Bignell, G.R., Cox, C. et al. (2002). Mutations of the BRAF gene in human cancer. Nature 417, 949 954.
28. Dean, M., Fojo, T. Bates, S. (2005). Tumour stem cells and drug resistance. Nat. Rev. Cancer 5, 275 284.
29. Deheuninck, J. Luo, K. (2009). Ski and SnoN, potent negative regulators of TGF-beta signaling. Cell Res. 19, 47 57.
30. Demicheli, R. (2001). Tumour dormancy: findings and hypotheses from clinical research on breast cancer. Semin. Cancer Biol. 11, 297 306.
31. Deng, X., Ewton, D.Z. Friedman, E. (2009). Mirk/Dyrk1B maintains the viability of quiescent pancreatic cancer cells by reducing levels of reactive oxygen species. Cancer Res. 69, 3317 3324.
32. Denoyelle, C., Abou-Rjaily, G., Bezrookove, V. et al. (2006). Anti-oncogenic role of the endoplasmic reticulum differentially activated by mutations in the MAPK pathway. Nat. Cell Biol. 8, 1053 1063.
33. Dhomen, N. Marais, R. (2009). BRAF signaling and targeted therapies in melanoma. Hematol. Oncol. Clin. North Am. 23, 529 545, ix.
34. Dhomen, N., Reis-Filho, J.S., Da Rocha Dias, S., Hayward, R., Savage, K., Delmas, V., Larue, L., Pritchard, C. Marais, R. (2009). Oncogenic Braf induces melanocyte senescence and melanoma in mice. Cancer Cell 15, 294 303.
35. Dimos, J.T., Rodolfa, K.T., Niakan, K.K. et al. (2008). Induced pluripotent stem cells generated from patients with ALS can be differentiated into motor neurons. Science 321, 1218 1221.
36. Ducos, K., Panterne, B., Fortunel, N., Hatzfeld, A., Monier, M.N. Hatzfeld, J. (2000). p21(cip1) mRNA is controlled by endogenous transforming growth factor-beta1 in quiescent human hematopoietic stem/progenitor cells. J. Cell. Physiol. 184, 80 85.
37. Dunn, G.P., Lewis, J.S. Jr., Sunwoo, J.B. Uppaluri, R. (2008). Spontaneous regression of cutaneous head and neck melanoma: implications for the immunologic control of neoplasia. Head Neck 30, 267 272.
38. Eskelin, S., Pyrhonen, S., Summanen, P., Hahka-Kemppinen, M. Kivela, T. (2000). Tumor doubling times in metastatic malignant melanoma of the uvea: tumor progression before and after treatment. Ophthalmology 107, 1443 1449.
39. Estrada, Y., Dong, J. Ossowski, L. (2009). Positive crosstalk between ERK and p38 in melanoma stimulates migration and in vivo proliferation. Pigment Cell Melanoma Res. 22, 66 76.
40. Fang, D., Nguyen, T.K., Leishear, K., Finko, R., Kulp, A.N., Hotz, S., Van Belle, P.A., Xu, X., Elder, D.E. Herlyn, M. (2005). A tumorigenic subpopulation with stem cell properties in melanomas. Cancer Res. 65, 9328 9337.
41. Felsher, D.W. (2008a). Oncogene addiction versus oncogene amnesia: perhaps more than just a bad habit? Cancer Res. 68, 3081 3086 discussion 3086.
42. Felsher, D.W. (2008b). Tumor dormancy and oncogene addiction. APMIS 116, 629 637.
43. Ferrari, D., Lombardi, M., Ricci, R., Michiara, M., Santini, M. De Panfilis, G. (2007). Dermatopathological indicators of poor melanoma prognosis are significantly inversely correlated with the expression of NM23 protein in primary cutaneous melanoma. J. Cutan. Pathol. 34, 705 712.
44. Fidler, I.J. (1983). The Ernst W. Bertner Memorial Award lecture: the evolution of biological heterogeneity in metastatic neoplasms. Symp. Fundam. Cancer Res. 36, 5 26.
45. Finn, O.J. (2006). Human tumor antigens, immunosurveillance, and cancer vaccines. Immunol. Res. 36, 73 82.
46. Fisher, B. Fisher, E.R. (1959). Experimental evidence in support of the dormant tumor cell. Science 130, 918 919.
47. Florenes, V.A., Bhattacharya, N., Bani, M.R., Ben-David, Y., Kerbel, R.S. Slingerland, J.M. (1996). TGF-beta mediated G1 arrest in a human melanoma cell line lacking p15INK4B: evidence for cooperation between p21Cip1/WAF1 and p27Kip1. Oncogene 13, 2447 2457.
48. Foulds, L. (1957). Tumor progression. Cancer Res. 17, 355 356.
49. Frank, N.Y., Margaryan, A., Huang, Y., Schatton, T., Waaga-Gasser, A.M., Gasser, M., Sayegh, M.H., Sadee, W. Frank, M.H. (2005). ABCB5-mediated doxorubicin transport and chemoresistance in human malignant melanoma. Cancer Res. 65, 4320 4333.
50. Gajewski, T.F. (2006). Identifying and overcoming immune resistance mechanisms in the melanoma tumor microenvironment. Clin. Cancer Res. 12, 2326s 2330s.
51. Gamel, J.W., George, S.L., Edwards, M.J. Seigler, H.F. (2002). The long-term clinical course of patients with cutaneous melanoma. Cancer 95, 1286 1293.
52. Gottesman, M.M. (2002). Mechanisms of cancer drug resistance. Annu. Rev. Med. 53, 615 627.
53. Grichnik, J.M. (2008). Melanoma, nevogenesis, and stem cell biology. J. Invest. Dermatol. 128, 2365 2380.
54. Guldberg, P., Thor Straten, P., Birck, A., Ahrenkiel, V., Kirkin, A.F. Zeuthen, J. (1997). Disruption of the MMAC1/PTEN gene by deletion or mutation is a frequent event in malignant melanoma. Cancer Res. 57, 3660 3663.
55. Gutman, M., Klausner, J.M., Inbar, M. Rozin, R.R. (1989). Late recurrence of stage I malignant melanoma. J. Surg. Oncol. 42, 96 98.
56. Haluska, F., Pemberton, T., Ibrahim, N. Kalinsky, K. (2007). The RTK/RAS/BRAF/PI3K pathways in melanoma: biology, small molecule inhibitors, and potential applications. Semin. Oncol. 34, 546 554.
57. Henriet, P., Zhong, Z.D., Brooks, P.C., Weinberg, K.I. Declerck, Y.A. (2000). Contact with fibrillar collagen inhibits melanoma cell proliferation by up-regulating p27KIP1. Proc. Natl Acad. Sci. USA 97, 10026 10031.
58. Hoek, K.S., Eichhoff, O.M., Schlegel, N.C., Dobbeling, U., Kobert, N., Schaerer, L., Hemmi, S. Dummer, R. (2008). In vivo switching of human melanoma cells between proliferative and invasive states. Cancer Res. 68, 650 656.
59. Hsu, M.Y., Meier, F.E., Nesbit, M., Hsu, J.Y., Van Belle, P., Elder, D.E. Herlyn, M. (2000). E-cadherin expression in melanoma cells restores keratinocyte-mediated growth control and down-regulates expression of invasion-related adhesion receptors. Am. J. Pathol. 156, 1515 1525.
60. Hsu, M.Y., Rovinsky, S., Penmatcha, S., Herlyn, M. Muirhead, D. (2005). Bone morphogenetic proteins in melanoma: angel or devil? Cancer Metastasis Rev. 24, 251 263.
61. Husemann, Y., Geigl, J.B., Schubert, F. et al. (2008). Systemic spread is an early step in breast cancer. Cancer Cell 13, 58 68.
62. Hussein, M.R. (2005). Transforming growth factor-beta and malignant melanoma: molecular mechanisms. J. Cutan. Pathol. 32, 389 395.
63. Jarriault, S., Brou, C., Logeat, F., Schroeter, E.H., Kopan, R. Israel, A. (1995). Signalling downstream of activated mammalian Notch. Nature 377, 355 358.
64. Javelaud, D., Alexaki, V.I. Mauviel, A. (2008). Transforming growth factor-beta in cutaneous melanoma. Pigment Cell Melanoma Res. 21, 123 132.
65. Kalinec, G., Nazarali, A.J., Hermouet, S., Xu, N. Gutkind, J.S. (1992). Mutated alpha subunit of the Gq protein induces malignant transformation in NIH 3T3 cells. Mol. Cell. Biol. 12, 4687 4693.
66. Kalinsky, K. Haluska, F.G. (2007). Novel inhibitors in the treatment of metastatic melanoma. Expert Rev. Anticancer Ther. 7, 715 724.
67. Kelly, P.N., Dakic, A., Adams, J.M., Nutt, S.L. Strasser, A. (2007). Tumor growth need not be driven by rare cancer stem cells. Science 317, 337.
68. Kim, J.B., Zaehres, H., Wu, G. et al. (2008). Pluripotent stem cells induced from adult neural stem cells by reprogramming with two factors. Nature 454, 646 650.
69. Klein, C.A. (2008). The direct molecular analysis of metastatic precursor cells in breast cancer: a chance for a better understanding of metastasis and for personalised medicine. Eur. J. Cancer 44, 2721 2725.
70. Klein, C.A. Hölzel, D. (2006). Systemic cancer progression and tumor dormancy: mathematical models meet single cell genomics. Cell Cycle 5, 1788 1798.
71. Klein, W.M., Wu, B.P., Zhao, S., Wu, H., Klein-Szanto, A.J. Tahan, S.R. (2007). Increased expression of stem cell markers in malignant melanoma. Mod. Pathol. 20, 102 107.
72. Koebel, C.M., Vermi, W., Swann, J.B., Zerafa, N., Rodig, S.J., Old, L.J., Smyth, M.J. Schreiber, R.D. (2007). Adaptive immunity maintains occult cancer in an equilibrium state. Nature 450, 903 907.
73. Kortylewski, M., Heinrich, P.C., Kauffmann, M.E., Bohm, M., Mackiewicz, A. Behrmann, I. (2001). Mitogen-activated protein kinases control p27/Kip1 expression and growth of human melanoma cells. Biochem. J. 357, 297 303.
74. Kumar, R., Angelini, S., Czene, K., Sauroja, I., Hahka-Kemppinen, M., Pyrhonen, S. Hemminki, K. (2003). BRAF mutations in metastatic melanoma: a possible association with clinical outcome. Clin. Cancer Res. 9, 3362 3368.
75. Lahlou, H., Sanguin-Gendreau, V., Zuo, D., Cardiff, R.D., Mclean, G.W., Frame, M.C. Muller, W.J. (2007). Mammary epithelial-specific disruption of the focal adhesion kinase blocks mammary tumor progression. Proc. Natl Acad. Sci. USA 104, 20302 20307.
76. Le Scolan, E., Zhu, Q., Wang, L., Bandyopadhyay, A., Javelaud, D., Mauviel, A., Sun, L. Luo, K. (2008). Transforming growth factor-beta suppresses the ability of Ski to inhibit tumor metastasis by inducing its degradation. Cancer Res. 68, 3277 3285.
77. Lefevre, G., Calipel, A., Mouriaux, F., Hecquet, C., Malecaze, F. Mascarelli, F. (2003). Opposite long-term regulation of c-Myc and p27Kip1 through overactivation of Raf-1 and the MEK/ERK module in proliferating human choroidal melanoma cells. Oncogene 22, 8813 8822.
78. Lengagne, R., Graff-Dubois, S., Garcette, M., Renia, L., Kato, M., Guillet, J.G., Engelhard, V.H., Avril, M.F., Abastado, J.P. Prevost-Blondel, A. (2008). Distinct role for CD8 T cells toward cutaneous tumors and visceral metastases. J. Immunol. 180, 130 137.
79. Liang, J., Zubovitz, J., Petrocelli, T. et al. (2002). PKB/Akt phosphorylates p27, impairs nuclear import of p27 and opposes p27-mediated G1 arrest. Nat. Med. 8, 1153 1160.
80. Liang, J., Shao, S.H., Xu, Z.X. et al. (2007). The energy sensing LKB1-AMPK pathway regulates p27(kip1) phosphorylation mediating the decision to enter autophagy or apoptosis. Nat. Cell Biol. 9, 218 224.
81. Lin, H.K., Wang, G., Chen, Z. et al. (2009). Phosphorylation-dependent regulation of cytosolic localization and oncogenic function of Skp2 by Akt/PKB. Nat. Cell Biol. 11, 420 432.
82. Liu, D., Aguirre Ghiso, J., Estrada, Y. Ossowski, L. (2002). EGFR is a transducer of the urokinase receptor initiated signal that is required for in vivo growth of a human carcinoma. Cancer Cell 1, 445 457.
83. Liu, Z.J., Xiao, M., Balint, K., Smalley, K.S., Brafford, P., Qiu, R., Pinnix, C.C., Li, X. Herlyn, M. (2006). Notch1 signaling promotes primary melanoma progression by activating mitogen-activated protein kinase/phosphatidylinositol 3-kinase-Akt pathways and up-regulating N-cadherin expression. Cancer Res. 66, 4182 4190.
84. Logan, P.T., Fernandes, B.F., Di Cesare, S., Marshall, J.C., Maloney, S.C. Burnier, M.N. Jr. (2008). Single-cell tumor dormancy model of uveal melanoma. Clin. Exp. Metastasis 25, 509 516.
85. Lopez-Bergami, P., Huang, C., Goydos, J.S. et al. (2007). Rewired ERK-JNK signaling pathways in melanoma. Cancer Cell 11, 447 460.
86. Lopez-Bergami, P., Fitchman, B. Ronai, Z. (2008). Understanding signaling cascades in melanoma. Photochem. Photobiol. 84, 289 306.
87. Lorigan, P., Eisen, T. Hauschild, A. (2008). Systemic therapy for metastatic malignant melanoma-from deeply disappointing to bright future? Exp. Dermatol. 17, 383 394.
88. Mackie, R.M., Reid, R. Junor, B. (2003). Fatal melanoma transferred in a donated kidney 16 years after melanoma surgery. N. Engl. J. Med. 348, 567 568.
89. Mahabeleshwar, G.H. Byzova, T.V. (2007). Angiogenesis in melanoma. Semin. Oncol. 34, 555 565.
90. Mahnke, Y.D., Schwendemann, J., Beckhove, P. Schirrmacher, V. (2005). Maintenance of long-term tumour-specific T-cell memory by residual dormant tumour cells. Immunology 115, 325 336.
91. Mani, S.A., Guo, W., Liao, M.J. et al. (2008). The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 133, 704 715.
92. Marches, R., Scheuermann, R.H. Uhr, J.W. (1998). Cancer dormancy: role of cyclin-dependent kinase inhibitors in induction of cell cycle arrest mediated via membrane IgM. Cancer Res. 58, 691 697.
93. Marches, R., Hsueh, R. Uhr, J.W. (1999). Cancer dormancy and cell signaling: induction of p21(waf1) initiated by membrane IgM engagement increases survival of B lymphoma cells. Proc. Natl Acad. Sci. USA 96, 8711 8715.
94. Marches, R., Scheuermann, R.H. Uhr, J. (2006). Cancer dormancy from mice to man: a review. Cell Cycle 5, 1772 1778.
95. Mirmohammadsadegh, A., Marini, A., Nambiar, S., Hassan, M., Tannapfel, A., Ruzicka, T. Hengge, U.R. (2006). Epigenetic silencing of the PTEN gene in melanoma. Cancer Res. 66, 6546 6552.
96. Monzani, E., Facchetti, F., Galmozzi, E. et al. (2007). Melanoma contains CD133 and ABCG2 positive cells with enhanced tumourigenic potential. Eur. J. Cancer 43, 935 946.
97. Nash, K.T., Phadke, P.A., Navenot, J.M. et al. (2007). Requirement of KISS1 secretion for multiple organ metastasis suppression and maintenance of tumor dormancy. J. Natl Cancer Inst. 99, 309 321.
98. Naumov, G.N., Akslen, L.A. Folkman, J. (2006). Role of angiogenesis in human tumor dormancy: animal models of the angiogenic switch. Cell Cycle 5, 1779 1787. (Pubitemid 44435320)
99. Nickoloff, B.J., Hendrix, M.J., Pollock, P.M., Trent, J.M., Miele, L. Qin, J.Z. (2005). Notch and NOXA-related pathways in melanoma cells. J. Investig. Dermatol. Symp. Proc. 10, 95 104.
100. Niederkorn, J.Y. (2009). Immune escape mechanisms of intraocular tumors. Prog. Retin. Eye Res. 28, 329 347.
101. Nowell, P.C. (2002). Tumor progression: a brief historical perspective. Semin. Cancer Biol. 12, 261 266.
102. Odoux, C., Fohrer, H., Hoppo, T., Guzik, L., Stolz, D.B., Lewis, D.W., Gollin, S.M., Gamblin, T.C., Geller, D.A. Lagasse, E. (2008). A stochastic model for cancer stem cell origin in metastatic colon cancer. Cancer Res. 68, 6932 6941.
103. Onken, M.D., Worley, L.A., Long, M.D., Duan, S., Council, M.L., Bowcock, A.M. Harbour, J.W. (2008). Oncogenic mutations in GNAQ occur early in uveal melanoma. Invest. Ophthalmol. Vis. Sci. 49, 5230 5234.
104. Ossowski, L. Reich, E. (1980). Loss of malignancy during serial passage of human carcinoma in culture and discordance between malignancy and transformation parameters. Cancer Res. 40, 2310 2315.
105. Ossowski, L. Reich, E. (1983). Changes in malignant phenotype of a human carcinoma conditioned by growth environment. Cell 33, 323 333.
106. Paget, S. (1889). The distribution of secondary growths in cancer of the breast. Lancet 1, 571 573.
107. Pantel, K. Brakenhoff, R.H. (2004). Dissecting the metastatic cascade. Nat. Rev. Cancer 4, 448 456.
108. Pantel, K., Alix-Panabieres, C. Riethdorf, S. (2009). Cancer micrometastases. Nat. Rev. Clin. Oncol. 6, 339 351.
109. Pelayo, R., Miyazaki, K., Huang, J., Garrett, K.P., Osmond, D.G. Kincade, P.W. (2006). Cell cycle quiescence of early lymphoid progenitors in adult bone marrow. Stem Cells 24, 2703 2713.
110. Penn, I. (1996). Malignant melanoma in organ allograft recipients. Transplantation 61, 274 278.
111. Peters, A., Lippold, A. Hundeiker, M. (1997). First melanoma metastases after 10 years and more of remission. Hautarzt 48, 311 317.
112. Pharis, D.B. (2005). Cutaneous melanoma: therapeutic lymph node and elective lymph node dissections, lymphatic mapping, and sentinel lymph node biopsy. Dermatol. Ther. 18, 397 406.
113. Pinnix, C.C., Lee, J.T., Liu, Z.J. et al. (2009). Active Notch1 confers a transformed phenotype to primary human melanocytes. Cancer Res. 69, 5312 5320.
114. Polak, M.E., Borthwick, N.J., Jager, M.J. Cree, I.A. (2009). Melanoma vaccines: the problems of local immunosuppression. Hum. Immunol. 70, 331 339.
115. Postovit, L.M., Seftor, E.A., Seftor, R.E. Hendrix, M.J. (2006). A three-dimensional model to study the epigenetic effects induced by the microenvironment of human embryonic stem cells. Stem Cells 24, 501 505.
116. Quintana, E., Shackleton, M., Sabel, M.S., Fullen, D.R., Johnson, T.M. Morrison, S.J. (2008). Efficient tumour formation by single human melanoma cells. Nature 456, 593 598.
117. Rabinovsky, R., Uhr, J.W., Vitetta, E.S. Yefenof, E. (2007). Cancer dormancy: lessons from a B cell lymphoma and adenocarcinoma of the prostate. Adv. Cancer Res. 97, 189 202.
118. Ralph, S.J. (2007). An update on malignant melanoma vaccine research: insights into mechanisms for improving the design and potency of melanoma therapeutic vaccines. Am. J. Clin. Dermatol. 8, 123 141.
119. Ranganathan, A.C., Zhang, L., Adam, A.P. Aguirre-Ghiso, J.A. (2006). Functional coupling of p38-induced up-regulation of BiP and activation of RNA-dependent protein kinase-like endoplasmic reticulum kinase to drug resistance of dormant carcinoma cells. Cancer Res. 66, 1702 1711.
120. Reed, J.A., Bales, E., Xu, W., Okan, N.A., Bandyopadhyay, D. Medrano, E.E. (2001). Cytoplasmic localization of the oncogenic protein Ski in human cutaneous melanomas in vivo: functional implications for transforming growth factor beta signaling. Cancer Res. 61, 8074 8078.
121. Richards, H.W. Medrano, E.E. (2009). Epigenetic marks in melanoma. Pigment Cell Melanoma Res. 22, 14 29.
122. Rosen, J.M. Jordan, C.T. (2009). The increasing complexity of the cancer stem cell paradigm. Science 324, 1670 1673.
123. Rosenblatt, M.I. Azar, D.T. (2006). Anti-angiogenic therapy: prospects for treatment of ocular tumors. Semin. Ophthalmol. 21, 151 160.
124. Rothhammer, T. Bosserhoff, A.K. (2007). Epigenetic events in malignant melanoma. Pigment Cell Res. 20, 92 111.
125. Sabatino, M., Stroncek, D.F., Klein, H., Marincola, F.M. Wang, E. (2009). Stem cells in melanoma development. Cancer Lett. 279, 119 125.
126. Sang, L., Coller, H.A. Roberts, J.M. (2008). Control of the reversibility of cellular quiescence by the transcriptional repressor HES1. Science 321, 1095 1100.
127. Sanki, A., Li, W., Colman, M., Karim, R.Z., Thompson, J.F. Scolyer, R.A. (2007). Reduced expression of p16 and p27 is correlated with tumour progression in cutaneous melanoma. Pathology 39, 551 557.
128. Saudemont, A. Quesnel, B. (2004). In a model of tumor dormancy, long-term persistent leukemic cells have increased B7-H1 and B7.1 expression and resist CTL-mediated lysis. Blood 104, 2124 2133.
129. Schardt, J.A., Meyer, M., Hartmann, C.H., Schubert, F., Schmidt-Kittler, O., Fuhrmann, C., Polzer, B., Petronio, M., Eils, R. Klein, C.A. (2005). Genomic analysis of single cytokeratin-positive cells from bone marrow reveals early mutational events in breast cancer. Cancer Cell 8, 227 239.
130. Schatton, T., Murphy, G.F., Frank, N.Y. et al. (2008). Identification of cells initiating human melanomas. Nature 451, 345 349.
131. Schewe, D.M. Aguirre-Ghiso, J.A. (2008). ATF6alpha-Rheb-mTOR signaling promotes survival of dormant tumor cells in vivo. Proc. Natl Acad. Sci. USA 105, 10519 10524.
132. Schlegel, N.C., Eichhoff, O.M., Hemmi, S., Werner, S., Dummer, R. Hoek, K.S. (2009). Id2 suppression of p15 counters TGF-beta-mediated growth inhibition of melanoma cells. Pigment Cell Melanoma Res. 22, 445 453.
133. Schmidt-Kittler, O., Ragg, T., Daskalakis, A. et al. (2003). From latent disseminated cells to overt metastasis: genetic analysis of systemic breast cancer progression. Proc. Natl Acad. Sci. USA 100, 7737 7742.
134. Schmid-Wendtner, M.H., Baumert, J., Schmidt, M., Konz, B., Holzel, D., Plewig, G. Volkenandt, M. (2000). Late metastases of cutaneous melanoma: an analysis of 31 patients. J. Am. Acad. Dermatol. 43, 605 609.
135. Schuster, R., Bechrakis, N.E., Stroux, A., Busse, A., Schmittel, A., Scheibenbogen, C., Thiel, E., Foerster, M.H. Keilholz, U. (2007). Circulating tumor cells as prognostic factor for distant metastases and survival in patients with primary uveal melanoma. Clin. Cancer Res. 13, 1171 1178.
136. Sharma, S.V., Gajowniczek, P., Way, I.P., Lee, D.Y., Jiang, J., Yuza, Y., Classon, M., Haber, D.A. Settleman, J. (2006). A common signaling cascade may underlie "addiction" to the Src, BCR-ABL, and EGF receptor oncogenes. Cancer Cell 10, 425 435.
137. Shen, P., Guenther, J.M., Wanek, L.A. Morton, D.L. (2000). Can elective lymph node dissection decrease the frequency and mortality rate of late melanoma recurrences? Ann. Surg. Oncol. 7, 114 119.
138. Shibue, T. Weinberg, R.A. (2009). Integrin beta1-focal adhesion kinase signaling directs the proliferation of metastatic cancer cells disseminated in the lungs. Proc. Natl Acad. Sci. USA 106, 10290 10295.
139. Shildkrot, Y. Wilson, M.W. (2009). Update on posterior uveal melanoma: treatment of the eye and emerging strategies in the prognosis and treatment of metastatic disease. Curr. Opin. Ophthalmol., 20, 504 510.
140. Shinozaki, M., Fujimoto, A., Morton, D.L. Hoon, D.S. (2004). Incidence of BRAF oncogene mutation and clinical relevance for primary cutaneous melanomas. Clin. Cancer Res. 10, 1753 1757.
141. Stoecklein, N.H., Hosch, S.B., Bezler, M. et al. (2008). Direct genetic analysis of single disseminated cancer cells for prediction of outcome and therapy selection in esophageal cancer. Cancer Cell 13, 441 453.
142. Terando, A.M., Faries, M.B. Morton, D.L. (2007). Vaccine therapy for melanoma: current status and future directions. Vaccine 25 (Suppl 2 B4 B16.
143. Townson, J.L. Chambers, A.F. (2006). Dormancy of solitary metastatic cells. Cell Cycle 5, 1744 1750.
144. Triozzi, P.L., Eng, C. Singh, A.D. (2008). Targeted therapy for uveal melanoma. Cancer Treat. Rev. 34, 247 258.
145. Tsao, H., Cosimi, A.B. Sober, A.J. (1997). Ultra-late recurrence (15 years or longer) of cutaneous melanoma. Cancer 79, 2361 2370.
146. Ulmer, A., Beutel, J., Susskind, D. et al. (2008). Visualization of circulating melanoma cells in peripheral blood of patients with primary uveal melanoma. Clin. Cancer Res. 14, 4469 4474.
147. Umansky, V., Abschuetz, O., Osen, W., Ramacher, M., Zhao, F., Kato, M. Schadendorf, D. (2008). Melanoma-specific memory T cells are functionally active in Ret transgenic mice without macroscopic tumors. Cancer Res. 68, 9451 9458.
148. Van Raamsdonk, C.D., Bezrookove, V., Green, G., Bauer, J., Gaugler, L., O'brien, J.M., Simpson, E.M., Barsh, G.S. Bastian, B.C. (2009). Frequent somatic mutations of GNAQ in uveal melanoma and blue naevi. Nature 457, 599 602.
149. Vessella, R.L., Pantel, K. Mohla, S. (2007). Tumor cell dormancy: an NCI workshop report. Cancer Biol. Ther. 6, 1496 1504.
150. Visús, C., Andres, R., Mayordomo, J.I. et al. (2007). Prognostic role of circulating melanoma cells detected by reverse transcriptase-polymerase chain reaction for tyrosinase mRNA in patients with melanoma. Melanoma Res. 73, 83 89.
151. Wajapeyee, N., Serra, R.W., Zhu, X., Mahalingam, M. Green, M.R. (2008). Oncogenic BRAF induces senescence and apoptosis through pathways mediated by the secreted protein IGFBP7. Cell 132, 363 374.
152. Wall, S.J., Werner, E., Werb, Z. Declerck, Y.A. (2005). Discoidin domain receptor 2 mediates tumor cell cycle arrest induced by fibrillar collagen. J. Biol. Chem. 280, 40187 40194.
153. Wall, S.J., Zhong, Z.D. Declerck, Y.A. (2007). The cyclin-dependent kinase inhibitors p15INK4B and p21CIP1 are critical regulators of fibrillar collagen-induced tumor cell cycle arrest. J. Biol. Chem. 282, 24471 24476.
154. Weinstein, I.B. (2002). Cancer. Addiction to oncogenes-the Achilles heal of cancer. Science 297, 63 64.
155. White, D.E., Kurpios, N.A., Zuo, D., Hassell, J.A., Blaess, S., Mueller, U. Muller, W.J. (2004). Targeted disruption of beta1-integrin in a transgenic mouse model of human breast cancer reveals an essential role in mammary tumor induction. Cancer Cell 6, 159 170.
156. Whiteman, D.C., Zhou, X.P., Cummings, M.C., Pavey, S., Hayward, N.K. Eng, C. (2002). Nuclear PTEN expression and clinicopathologic features in a population-based series of primary cutaneous melanoma. Int. J. Cancer 99, 63 67.
157. Wikman, H., Vessella, R. Pantel, K. (2008). Cancer micrometastasis and tumour dormancy. APMIS 116, 754 770.
158. Willimsky, G. Blankenstein, T. (2005). Sporadic immunogenic tumours avoid destruction by inducing T-cell tolerance. Nature 437, 141 146.
159. Wilson, A., Laurenti, E., Oser, G. et al. (2008). Hematopoietic stem cells reversibly switch from dormancy to self-renewal during homeostasis and repair. Cell 135, 1118 1129.
160. Xia, S., Lu, Y., Wang, J., He, C., Hong, S., Serhan, C.N. Kang, J.X. (2006). Melanoma growth is reduced in fat-1 transgenic mice: impact of omega-6/omega-3 essential fatty acids. Proc. Natl Acad. Sci. USA 103, 12499 12504.
161. Zapas, J.L., Coley, H.C., Beam, S.L., Brown, S.D., Jablonski, K.A. Elias, E.G. (2003). The risk of regional lymph node metastases in patients with melanoma less than 1.0 mm thick: recommendations for sentinel lymph node biopsy. J. Am. Coll. Surg. 197, 403 407.
162. Zhou, X.P., Gimm, O., Hampel, H., Niemann, T., Walker, M.J. Eng, C. (2000). Epigenetic PTEN silencing in malignant melanomas without PTEN mutation. Am. J. Pathol. 157, 1123 1128.